HK1255193A1 - 優化的含有高劑量美沙拉嗪的片劑 - Google Patents

優化的含有高劑量美沙拉嗪的片劑

Info

Publication number
HK1255193A1
HK1255193A1 HK18114316.8A HK18114316A HK1255193A1 HK 1255193 A1 HK1255193 A1 HK 1255193A1 HK 18114316 A HK18114316 A HK 18114316A HK 1255193 A1 HK1255193 A1 HK 1255193A1
Authority
HK
Hong Kong
Prior art keywords
containing tablet
mesalazine
dose
optimised high
optimised
Prior art date
Application number
HK18114316.8A
Other languages
English (en)
Inventor
Rudolph Wilhelm
Markus Pröls
Roland Greinwald
Tanju Nacak
Original Assignee
福爾克博士藥物有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 福爾克博士藥物有限責任公司 filed Critical 福爾克博士藥物有限責任公司
Publication of HK1255193A1 publication Critical patent/HK1255193A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18114316.8A 2015-10-30 2018-11-08 優化的含有高劑量美沙拉嗪的片劑 HK1255193A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15192269.7A EP3162362A1 (de) 2015-10-30 2015-10-30 Optimierte mesalazinhaltige hochdosistablette
PCT/EP2016/075427 WO2017072050A1 (de) 2015-10-30 2016-10-21 Optimierte mesalazinhaltige hochdosistablette

Publications (1)

Publication Number Publication Date
HK1255193A1 true HK1255193A1 (zh) 2019-08-09

Family

ID=54476727

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114316.8A HK1255193A1 (zh) 2015-10-30 2018-11-08 優化的含有高劑量美沙拉嗪的片劑

Country Status (21)

Country Link
US (1) US11135159B2 (zh)
EP (2) EP3162362A1 (zh)
JP (1) JP6872135B2 (zh)
KR (1) KR20180077246A (zh)
CN (2) CN117180218A (zh)
AU (1) AU2016347352B2 (zh)
CA (1) CA3001435A1 (zh)
CY (1) CY1122473T1 (zh)
DK (1) DK3368017T3 (zh)
EA (1) EA201890828A1 (zh)
ES (1) ES2761319T3 (zh)
HK (1) HK1255193A1 (zh)
HR (1) HRP20192184T1 (zh)
HU (1) HUE046593T2 (zh)
LT (1) LT3368017T (zh)
MX (1) MX2018005358A (zh)
PL (1) PL3368017T3 (zh)
PT (1) PT3368017T (zh)
RS (1) RS59748B1 (zh)
SI (1) SI3368017T1 (zh)
WO (1) WO2017072050A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
TR201722039A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3662895A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CA2444814C (en) * 2001-10-24 2009-06-09 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CN1314390C (zh) * 2001-11-23 2007-05-09 宝洁公司 具有多重包衣的药物剂型
CN1665490A (zh) * 2002-07-05 2005-09-07 特姆雷尔公司 控释组合物
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
WO2009140853A1 (en) * 2008-05-23 2009-11-26 The University Of Hong Kong Combination therapy for the treatment of influenza
US9463163B2 (en) * 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
PT2959892T (pt) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Comprimido com revestimento entérico
AU2013404367B2 (en) * 2013-10-29 2020-02-27 Tillotts Pharma Ag A delayed release drug formulation
IN2014MU00097A (zh) * 2014-01-10 2015-08-21 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
RS59748B1 (sr) 2020-02-28
WO2017072050A1 (de) 2017-05-04
DK3368017T3 (da) 2019-12-16
PL3368017T3 (pl) 2020-04-30
US20180311155A1 (en) 2018-11-01
KR20180077246A (ko) 2018-07-06
AU2016347352B2 (en) 2021-09-09
AU2016347352A1 (en) 2018-05-10
CY1122473T1 (el) 2021-01-27
PT3368017T (pt) 2020-01-06
HRP20192184T1 (hr) 2020-03-06
CN117180218A (zh) 2023-12-08
ES2761319T3 (es) 2020-05-19
EA201890828A1 (ru) 2018-11-30
EP3368017A1 (de) 2018-09-05
SI3368017T1 (sl) 2020-01-31
EP3162362A1 (de) 2017-05-03
HUE046593T2 (hu) 2020-03-30
CA3001435A1 (en) 2017-05-04
MX2018005358A (es) 2018-06-06
US11135159B2 (en) 2021-10-05
JP6872135B2 (ja) 2021-05-19
CN108348472A (zh) 2018-07-31
JP2018531960A (ja) 2018-11-01
EP3368017B1 (de) 2019-11-06
LT3368017T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
AU356804S (en) Tablet
HK1246711A1 (zh) 生物電子藥物
GB201706130D0 (en) No details
IL254818A0 (en) Ribociclib tablet
HK1255193A1 (zh) 優化的含有高劑量美沙拉嗪的片劑
GB201612542D0 (en) no details
GB201615071D0 (en) No details
HK1249857A1 (zh) 片劑
IL275360A (en) Optimal compounds
GB201420300D0 (en) Tablet
GB201616225D0 (en) No details
GB201420311D0 (en) Pharmaceutical processing
GB2544498B (en) Macerators
GB201702336D0 (en) No details
HK1202359A2 (zh) 哺乳器輔助固定裝置
GB201508480D0 (en) Cancer
AU356801S (en) Tablet
GB201417589D0 (en) Pharmaceutical Formulations
EP3431079C0 (en) COMPRESSED
GB201511252D0 (en) Tablet
GB201614498D0 (en) No details
ZA201604189B (en) Chute
TWM532873U (en) Tablet structure
GB201521840D0 (en) No details
GB201617092D0 (en) No details